ArticleBMJ open2026
Blood-based cell-free DNA for addressing colorectal cancer screening disparities: a study protocol for a randomised trial.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06929481 (Screening With Liquid Biopsies to Address Colorectal Cancer Inequities), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Screening With Liquid Biopsies to Address Colorectal Cancer Inequities
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionColorectal cancer (CRC) screening reduces cancer incidence and mortality, but participation rates are suboptimal in the USA and associated with inequities in CRC outcomes for lower income and many racial/ethnic minoritised groups. A novel, US Food and Drug Administration-approved cell-free tumour DNA (cfDNA) blood test has the potential to improve screening rates, but the impact of offering this test on participation, including among populations at disproportionately increased risk for inequities in CRC outcomes, has not been studied. We designed a small effectiveness randomised controlled trial (RCT) comparing a strategy of offering expanded options for CRC screening including a cfDNA test to a strategy of standard usual care options for screening. METHODS AND ANALYSIS: This study is a two-arm, parallel-group RCT, with 1:1 randomisation of 340 patients to an intervention group versus a usual care group for CRC screening. Participants will include patients who are aged 45-75, not up-to-date with CRC screening and attending a routine primary care visit at Family Health Centers of San Diego, a Federally Qualified Health Center (FQHC) system serving a racial and ethnically diverse, low-income patient population. The intervention group will be offered choice of colonoscopy, at home faecal immunochemical test (FIT) or a combination of in clinic cfDNA and at home FIT. The usual care group will be offered a choice of colonoscopy or at home FIT. Both groups will receive education on the importance of screening and reminders to complete testing. Primary outcome is CRC screening completion within 60 days of enrolment, summarised as the proportion of all patients randomised by group, compared via a χ ETHICS AND DISSEMINATION: This study was approved by the University of California, San Diego Office of Institutional Review Board Administration (811489). A waiver of documented (signed) consent was approved by and will allow for a pragmatic design that mimics usual care, in which all patients will be offered all options for CRC screening. Main results will be disseminated to trial participants via reporting of test results and study publication. TRIAL REGISTRATION NUMBER: NCT06929481.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.